Clinical trial · Observational
Metabolic Effects of Treatment in Intermediate and High-Risk Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will work towards understanding the changes in your body (metabolism) that develop with treatment in prostate cancer. Hormonal therapies such as ADT often result in detrimental changes in body composition, including lean tissue loss and fat gains, compared to those patients receiving radiation therapy. These changes in body composition are linked to risk of diabetes and cardiovascular disease in survivorship. The investigators will be evaluating 50 patients to primarily examine the changes in metabolism, nutrition, physical function and body composition at the end of treatment, 6 weeks and 6 months following the end of treatment. Patients will continue to be followed every 6 months for up to 5 years following the end of treatment. The investigators findings will provide a new perspective for future work and novel approaches in the treatment of prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- High-Risk Prostate Cancer
- label
- Intermediate-Risk Prostate Cancer
Primary outcomes (1)
- measure
- Change in Glucose Metabolism
- timeFrame
- Baseline, 7 weeks, 30 weeks
- description
- Oral glucose tolerance tests will be performed at each time point to assess changes in the body's ability to metabolize glucose. As such, other related parameters such as insulin and c-peptide will be measured to understand potential changes in glucose over the indicated time frame. As this is an observational study, safety issues are not anticipated. However, abnormal measures of glucose and insulin will be reported to a given participant's family physician.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Intermediate or high risk prostate cancer patients who have \>T2a or Gleason \>6 or PSA \>10 * Able to communicate in English * Have sufficient cognitive ability to participate and provide informed consent Exclusion Criteria: * Any known diagnosis of cardiovascular disease, diabetes, HIV, uncompensated thyroid disease * Pre-existing injuries or health conditions that prevents the patient's participation in exercise * Any previous diagnosis of cancer or anti-neoplastic treatment (other than melanoma skin cancer) which is not in remission for at least 3 years
References
Publications (0)
Data not yet available